Archives of Virology

, Volume 161, Issue 9, pp 2449–2455

VRC01 antibody protects against vaginal and rectal transmission of human immunodeficiency virus 1 in hu-BLT mice

  • Ming Sun
  • Yue Li
  • Zhe Yuan
  • Wuxun Lu
  • Guobin Kang
  • Wenjin Fan
  • Qingsheng Li
Original Article

DOI: 10.1007/s00705-016-2942-4

Cite this article as:
Sun, M., Li, Y., Yuan, Z. et al. Arch Virol (2016) 161: 2449. doi:10.1007/s00705-016-2942-4

Abstract

Broadly neutralizing antibodies (bNAbs) represent a new generation of antiviral agents for the prevention and treatment of human immunodeficiency virus 1 (HIV-1) infection. A better understanding of the in vivo efficacy of HIV-1 bNAbs, such as VRC01, in preventing mucosal transmission of HIV-1 has important implications for HIV-1 vaccine design. In this study, we evaluated the efficacy of passively transferred VRC01 antibody in preventing HIV-1 vaginal and rectal transmission in humanized bone marrow/liver/thymus mice (hu-BLT mice). Mice were subcutaneously injected with VRC01 IgG, and 24 hours later, they were challenged intravaginally or intrarectally with HIV-1Ada. All hu-BLT mice receiving VRC01 IgG antibody were aviremic at 2 weeks after intravaginal (n = 3) or intrarectal (n = 6) challenge as measured by quantitative real-time RT-PCR. In contrast, mice receiving control IgG all became infected. By 5 and 6 weeks post-challenge, some of VRC01 aviremic mice in both the intravaginal and intrarectal challenge groups became viremic. Our results suggest that VRC01 antibody can be protective against HIV-1 vaginal and rectal transmission; however, a single administration of VRC01 cannot completely prevent mucosal infection.

Supplementary material

705_2016_2942_MOESM1_ESM.xls (25 kb)
Supplemental Table 1 Quantification of human immune reconstitution in mice peripheral blood samples 12-16 weeks post-transplantation in this study using multi-parameter flow cytometry. The percentage of human leukocytes (human CD45+ and mouse CD45-) cells out of total leukocytes (FSC, SSC gating) in hu-BLT mouse blood and percentage of CD4+ T cells and CD8+ T cells out of total human T cells (human CD45+ and CD3+) at weeks 12 to 16 after surgery are also shown in this table.

Copyright information

© Springer-Verlag Wien 2016

Authors and Affiliations

  • Ming Sun
    • 1
    • 2
    • 3
  • Yue Li
    • 1
    • 2
    • 4
  • Zhe Yuan
    • 1
    • 2
  • Wuxun Lu
    • 1
    • 2
  • Guobin Kang
    • 1
    • 2
  • Wenjin Fan
    • 1
    • 2
  • Qingsheng Li
    • 1
    • 2
  1. 1.Nebraska Center for VirologyUniversity of Nebraska-LincolnLincolnUSA
  2. 2.School of Biological SciencesUniversity of Nebraska-LincolnLincolnUSA
  3. 3.Institute of Medical BiologyChinese Academy of Medical Science and Peking Union Medical CollegeKunmingChina
  4. 4.Key Laboratory of Molecular Microbiology and Technology, Ministry of Education, College of Life SciencesNankai UniversityTianjinChina

Personalised recommendations